EnteroMix

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

EnteroMix (Russian: ЭнтероМикс) is an experimental cancer immunotherapy under development in Russia. According to its developers, EnteroMix is a mixture of four oncolytic viruses—replication-competent human enteroviruses including Coxsackievirus A21, Echovirus 7, Enterovirus B75, and a modified derivative of a Sabin poliovirus vaccine strain—and is administered intravenously. , it is in Phase I clinical trials, which primarily assess safety, dosage, and preliminary tolerability, rather than effectiveness.

Evidence and sources

In May 2026, the trial was formally registered on ClinicalTrials.gov (identifier NCT07584668) under the investigational code EM-I-2024, providing the first internationally verifiable record of the ongoing Phase I study. EnteroMix gained widespread international media attention in late 2025, despite lack of publications in peer-reviewed journals internationally. Social media claims of high efficacy, imminent availability, and even ‘cure’ status have been shown to be exaggerated and misleading by independent fact-checking organizations.

EnteroMix (Russian: ЭнтероМикс) is an experimental cancer immunotherapy under development in Russia. According to its developers, EnteroMix is a mixture of four oncolytic viruses—replication-competent human enteroviruses including Coxsackievirus A21, Echovirus 7, Enterovirus B75, and a modified derivative of a Sabin poliovirus vaccine strain—and is administered intravenously. , it is in Phase I clinical trials, which primarily assess safety, dosage, and preliminary tolerability, rather than effectiveness.

In May 2026, the trial was formally registered on ClinicalTrials.gov (identifier NCT07584668) under the investigational code EM-I-2024, providing the first internationally verifiable record of the ongoing Phase I study. EnteroMix gained widespread international media attention in late 2025, despite lack of publications in peer-reviewed journals internationally. Social media claims of high efficacy, imminent availability, and even ‘cure’ status have been shown to be exaggerated and misleading by independent fact-checking organizations.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1366566680 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

34 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.